Page 204 - Mployee Wellness Programs News Today

Novocure’s electrical field-producing medical device, in combination with standard drug therapies, improved overall survival in a pivotal study that enrolled patients with advanced non-small cell lung cancer. The medtech company now plans to seek regulatory approvals.

Boston-based medical device company AVS recently raised $20 million in Series B funding to bring its arterial disease treatment closer to FDA clearance. The system that AVS is developing uses pressure waves to shatter calcium that has built up in arteries.

Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.

CommonSpirit Health is facing a proposed class-action lawsuit over a ransomware attack it suffered last fall that exposed 623,774 patients' personal data. However, hospitals' data breach lawsuits usually never make it court, a legal expert said.

This is a reversal from several years ago, when more Medicare Advantage beneficiaries switched to traditional Medicare, a recent report found. Medicare Advantage has grown in popularity over the last several years.

Hydreight recently launched an updated app so that the hundreds of nurses on its platform can have a more streamlined experience. Often referred to as "Uber for nurses," the platform allows nurses be their own boss and work as independent 1099 contractors.

By creating a marketplace that empowers consumers to choose the right health care coverage for their unique and individual needs, CMS will continue to put consumers first and strengthen Medicare Advantage, already the chosen program of America’s seniors.

Electronic Clinical Outcomes Assessment and digital health tools were well-suited to accommodate the rapid rise of virtual and telehealth shifts during the Covid-19 pandemic and there is no going back. The adoption of eCOA technology in mental healthcare research can make pivotal advancements in mental health patient care.

There’s a lingering misperception among many patients, loved ones, and even healthcare professionals that hospice care is useful only in a patient’s last days or weeks of life.

Fewer new drugs won FDA approvals in 2022 compared to previous years, but some of the products that passed regulatory muster are indicative of trends expected to continue into 2023. For example, more gene and cell therapies are on track to face regulatory decisions in the coming year.